Efficacy and safety of subanesthetic doses of esketamine combined with propofol in painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial

Yongtong Zhan†, Shuqing Liang†, Zecheng Yang†, Qichen Luo†, Shuai Li†, Jiamin Li‡, Zhaojia Liang†* and Yalan Li†*

Abstract

Background: Painless gastrointestinal endoscopy is widely used for the diagnosis and treatment of digestive diseases. At present, propofol is commonly used to perform painless gastrointestinal endoscopy, but the high dose of propofol often leads to a higher incidence of cardiovascular and respiratory complications. Studies have shown that the application of propofol combined with ketamine in painless gastrointestinal endoscopy is beneficial to reduce the dosage of propofol and the incidence of related complications. Esketamine is a dextrorotatory structure of ketamine with a twice as great anesthetic effect as normal ketamine but fewer side effects. We hypothesized that esketamine may reduce the consumption of propofol and to investigate the safety of coadministration during gastrointestinal endoscopy.

Methods: A total of 260 patients undergoing painless gastrointestinal endoscopy (gastroscope and colonoscopy) were randomly divided into P group (propofol + saline), PK1 group (propofol + esketamine 0.05 mg/kg), PK2 group (propofol + esketamine 0.1 mg/kg), and PK3 group (propofol + esketamine 0.2 mg/kg). Anesthesia was achieved by 1.5 mg/kg propofol with different doses of esketamine. Propofol consumption per minute was recorded. Hemodynamic index, pulse oxygen saturation, operative time, induction time, awakening status, orientation recovery time, adverse events, and Mini-Mental State Examination (MMSE) were also recorded during gastrointestinal endoscopy.

Results: Propofol consumption per minute was 11.78, 10.56, 10.14, and 9.57 (mg/min) in groups P, PK1, PK2, and PK3, respectively; compared with group P, groups PK2 and PK3 showed a decrease of 13.92% (P = 0.021) and 18.76% (P = 0.000), respectively. In all four groups, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), but not pulse oxygen saturation (SpO2) significantly decreased (P = 0.000) immediately after administration of induction, but there were no significant differences between the groups. The induction time of groups P, PK1, PK2, and PK3...
Background

Gastrointestinal (GI) endoscopy is the gold standard for the diagnosis of digestive tract diseases and is also widely used for the treatment of digestive tract diseases [1]. Almost half of the individuals underwent GI endoscopy without sedation reported pain or discomfort [2–4]. Poor pain management and patient’s anxiety can decrease procedure adherence [5]. The introduction of sedative agents during GI endoscopy help to relieve anxiety and pain. Painless GI endoscopy is much more popular with the administration of sedative agents, with more than 98% of GI endoscopies performed with sedation in the United States [6]. As the painless GI endoscopy has become popular among patients, it has also brought new challenges to anesthesiologists to deal with anesthesia complications such as hypotension, respiratory depression, nausea, vomiting, and even death.

When facing all these challenges, anesthesiologists must make an anesthesia plan before the GI procedure, ensuring that patients are stable and comfortable during the procedure, wake up quickly, and leave the hospital safely as soon as possible [7]. In clinical practice, propofol is one of the most commonly used drugs for painless GI endoscopy [8]. However, given that propofol does not have analgesic effects, large doses are needed to meet the requirements of painless GI endoscopy, which increases the risk of dose-related complications such as hypotension and hypoxemia [9, 10]. Therefore, it is appropriate to apply propofol in combination with other anesthetics, such as opioids (e.g., remifentanil, sufenta-nil), midazolam, etomidate, and ketamine, to reduce the consumption of propofol and the related complications. To date, there is no agreement on the optimal sedation regimen to facilitate GI endoscopy in an effective, safe, and satisfying manner for both patients and endoscopists [11].

Esketamine, an antagonist of the N-methyl-D-aspartic acid receptor, has analgesic and anesthetic effects and causes less cardiorespiratory and respiratory depression. It also leads to fewer psychotomimetic effects and less secretion [12, 13]. Therefore, it would be useful to examine whether there is any advantage in esketamine usage in painless GI endoscopy. We conducted a double-blinded, randomized controlled study to determine the safety and efficacy of subanesthetic doses of esketamine combined with propofol in painless GI endoscopy. We hypothesized that esketamine may reduce the consumption of propofol and that it is safe to coadminister propofol and esketamine during GI endoscopy.

Methods

Ethics and trial registration

China Ethics Committee of Registering Clinical Trials approved the protocol (Ethics Number: CHICRCTR20210050), and the study was registered in the Chinese Clinical Trial Registry (ChiCTR 2000039750; 07/11/2020). All participants signed the informed consent. The full trial protocol can be accessed at the following website: chictr.org.cn.

Inclusion and exclusion criteria

A prospective, double-blind, randomized controlled study was conducted at the First Affiliated Hospital of Jinan University. Between November 9, 2020, and September 1, 2021, patients scheduled for elective painless GI endoscopy were eligible for participation in this trial if they: (i) were 18–60 years old; (ii) had American Society of Anesthesiologists Physical Status (ASA PS) I to II; (iii) had a full understanding of the purpose and significance of this trial; and (iv) were able to sign an informed consent form.

Exclusion criteria were as follows: (i) a history of unregulated diabetes, hypertension, and hypotension; (ii) myocardial infarction within 6 months or unstable angina pectoris; (iii) III degree atroventricular block; (iv) severe snoring; (v) sleep apnea syndrome; (vi) decompensated liver function or renal function; (vii) dialysis treatment; (viii) psychosocial disease or cognitive dysfunction; (ix) a history of psychotropic drugs and narcotic drug abuse; (x) allergy to or contraindication for the drugs used in...
this study; (xi) participation in clinical trials of other
drugs within 3 months; (xii) other circumstances in
which the investigator determined that a patient was not
suitable for participation in the clinical trial.

Sample size estimation
According to our pre-experiment, the mean value and
standard deviation of propofol consumption per minute
in each group were obtained, and the inspection effi-
ciency was set at 0.90, while the inspection level was set
at 0.05. A required sample size of 62 subjects per group
was calculated using PASS 11 software (NCSS, Kaysville,
Utah). Considering a loss rate of 5%, a total of 260 sub-
jects (65 subjects per group) were required.

Randomization and blindness
The random sequence generator of STATA MP 14 soft-
ware generated 260 random numbers and divided
them into four groups. The patients were assigned
into four groups: group P (propofol); group PK1
(propofol + esketamine 0.05 mg/kg); group PK2
(propofol + esketamine 0.10 mg/kg); and group PK3
(propofol + esketamine 0.20 mg/kg). For each patient
enrolled, a researcher drew an envelope to determine
the patient’s grouping, but the patient was not informed
of the grouping. Except for propofol, clinical research-
ers were given syringes with clear solutions in the same
bottles with codes according to the randomization order.
The researchers who performed the randomization and
blinding procedure did not participate in the follow-
up study. Other investigators were not informed of the
grouping of the study and the experimental drugs. To
ensure allocation concealment, randomization results
were sealed until the end of the study.

Anesthesia sedation process
After routine GI endoscopy preparation and fasting
for 6 h before the procedure, the patients arrived at the
endoscopy center and were asked about basic informa-
tion. If the patients met the inclusion criteria, they signed
an informed consent form. Grouping was determined
according to the randomization. Before sedation, the
study drugs were diluted with normal saline in a 10 mL
syringe by a blindless nurse, with final concentrations of
0.5 mg/mL, 1 mg/mL, and 2 mg/mL for esketamine.

The procedure of sedation is shown in Fig. 1. In our
study, all participants underwent gastroscopy first and
then colonoscopy after anesthesia induction. They were
sedative through the whole procedure (gastroscopy and
colonoscopy). A 20 G IV cannula was inserted via the
anteecubital vein for fluid infusion. Standard monitoring
included blood pressure (BP), heart rate (HR), and pulse
oximetry (SPO$_2$) at T$_0$, followed by Mini-Mental State
Examination (MMSE) [14]. Data collection and MMSE
was performed by a blindness anesthesiologist who didn’t
take part in the administration of drugs.

Oxygen supplementation of 3 L/min was delivered via
a nasopharynx tube throughout the study. BP, HR, and
SPO$_2$ at T$_1$ were recorded 5 min before anesthesia induc-
tion. The patient was sedated by the same blindless anes-
thesiologist using the prepared test drug and propofol.
The same dose of normal saline (0.1 mL/kg), esketame-
ine (0.05 mg/kg, 0.10 mg/kg, and 0.20 mg/kg) for the P
group, PK1 group, PK2 group, and PK3 group, respec-
tively, were injected slowly (more than 6 s) followed by
1.5 mg/kg propofol for anesthesia induction. BP, HR, and
SPO$_2$ at T$_2$ were recorded immediately after administra-
tion of induction. When the patient’s eyelash reflex disa-
ppeared and there was no significant movement after the
gastroscope introduction, the same doctor at the endos-
copy center began to perform the endoscopy. BP, HR, and
SPO$_2$ at T$_3$ were recorded immediately after administra-
tion of insertion. A rescue dose of propofol (0.5 mg/kg) was
used if body movement, cough, or swallowing occurred
during the procedure. BP, HR, and SPO$_2$ were recorded immediately before (T$_4$) and after (T$_5$) colonoscopy. After
the GI endoscopy examination, the patient was roused
every 2 min. If the patient was able to open their eyes
and nod their head, the time of awakening was recorded.
Accordingly, 10 min after the patient awakened, MMSE was evaluated by the same anesthesiologist. During the operation process, SpO$_2$ < 95% was corrected by chin lifting, while SpO$_2$ < 90% was corrected by face mask ventilation. Phenylephrine 0.1 mg was injected when BP was below 30% of the baseline level, and atropine 0.25 mg was injected when HR was below 50/min. Other respiratory and cardiovascular adverse events were recorded and managed in accordance with the clinical operation standard. Before leaving the operating room, BP, HR, and SPO$_2$ (T6) as well as the ambulation time were recorded.

**Primary and secondary outcome**

The primary outcome of this study was propofol consumption per minute (mg/min). The total consumption of propofol and the duration of the procedure were recorded and then propofol consumption per minute was calculated. Secondary outcomes included hemodynamic index (T$_0$–T$_6$), induction time (from the injection of the study medication to the disappearance of eyelash reflex), procedure time (from the insertion of the gastroscope to the withdrawal of the colonoscope), delayed awakening (awakening time more than 6 min is defined as delayed awakening), orientation recovery time (consciousness return to normal walking), MMSE results, and adverse events. Adverse events included propofol injection pain, hypoxemia (SPO$_2$ < 95%), hypotension (blood pressure < 30% of the basal blood pressure or systolic blood pressure), hypertension (blood pressure > 30% of the basal blood pressure), arrhythmia, nausea and vomiting, dizziness, cough, body movement, apnea, excessive oral secretion, and psychotomimetic effects.

**Statistical analysis**

PASS 11 software was used to calculate the sample size. GraphPad Prism version 8.3.0 (San Diego, California) was used for statistical analysis. Continuous variables were shown as mean ± SD, and categorical variables were expressed as N (%) of patients. All data were checked for normal distribution using the Kolmogorov–Smirnov test and histograms. For continuous variables, ANOVA followed by Student–Newman–Keuls test was performed. For discrete variables, Kruskal–Wallis $H$ rank sum test followed by Tamhane’s T2 method was used. Repeated-measurement data were analyzed by ANOVA with a repeated-measurement design. For categorical variables, the pearson chi-square test or fisher’s exact test was applied. $P$ values < 0.05 were considered statistically significant.

**Results**

**Patient inclusion and characteristics**

Figure 2 shows the study flow diagram. There were 260 patients meeting the inclusion criteria and they were randomized into the study groups. The patients’ demographic characteristics and baseline values are shown in Table 1. There were no significant differences in the patients’ characteristics, comorbidities, and baseline values among the four groups.
Propofol consumption per minute
Propofol consumption per minute was 11.78, 10.56, 10.14, and 9.57 (mg/min) in groups P, PK1, PK2, and PK3, respectively (Fig. 3). Compared with group P, propofol consumption per minute in groups PK2 and PK3 decreased by 13.92% (\(P = 0.021\)) and 18.76% (\(P = 0.000\)), respectively. There were no significant differences in propofol consumption per minute among the three esketamine groups.

Hemodynamic results
SBP, DBP, HR, but not SpO₂ significantly decreased (\(P = 0.000\)) at T2, the time immediately after administration of induction. SBP, DBP, HR, and SpO₂ were significantly higher at T6 (\(P > 0.05\)), the time before patients left the operating room, compared with the baseline value (Fig. 4). The area under the curve (AUC) of SBP (\(P = 0.097\)), DBP (\(P = 0.253\)), HR (\(P = 0.838\)), and SpO₂ (\(P = 0.087\)) did not differ among the groups (Table 2). In general, there were no significant differences in hemodynamic parameters between the groups.

Table 1 Patients’ demographic characteristics

|                    | Group P         | Group PK1        | Group PK2        | Group PK3        | \(P\) value |
|--------------------|-----------------|------------------|------------------|------------------|-------------|
| Age (years)        | 44.94 ± 10.031  | 42.71 ± 10.148   | 45.89 ± 9.292    | 44.38 ± 10.233   | 0.785       |
| Gender (F)         | 38 (58.5%)      | 38 (58.5%)       | 32 (49.2%)       | 30 (46.2%)       | 0.369       |
| Weight (Kg)        | 61.32 ± 10.053  | 60.77 ± 9.465    | 62.97 ± 9.352    | 60.52 ± 9.816    | 0.918       |
| Height (cm)        | 164.20 ± 7.688  | 163.28 ± 7.966   | 165.12 ± 7.962   | 165.65 ± 7.787   | 0.969       |
| BMI                | 22.67 ± 2.755   | 22.74 ± 2.664    | 23.06 ± 2.770    | 21.99 ± 2.730    | 0.961       |
| ASA (I)            | 43 (66.2%)      | 39 (60.0%)       | 42 (64.6%)       | 42 (64.6%)       | 0.896       |
| Gastroscopy        | 65(100%)        | 65(100%)         | 65(100%)         | 65(100%)         |             |
| Colonoscopy        | 65(100%)        | 65(100%)         | 65(100%)         | 65(100%)         |             |
| Hypertension       | 19 (29.2%)      | 21 (32.3%)       | 19 (29.2%)       | 16 (24.6%)       | 0.812       |
| Diabetes           | 6 (9.2%)        | 2 (3.1%)         | 6 (9.2%)         | 3 (4.6%)         | 0.377       |
| Asthma             | 0 (0%)          | 0 (0%)           | 1 (1.5%)         | 0 (0%)           | 1.000       |
| COPD               | 0 (0%)          | 0 (0%)           | 0 (0%)           | 0 (0%)           | 1.000       |
| Tachycardia        | 7 (10.8%)       | 2 (3.1%)         | 8 (12.3%)        | 4 (6.2%)         | 0.194       |
| IHD                | 0 (0%)          | 1 (1.5%)         | 0 (0%)           | 0 (0%)           | 1.000       |
| Baseline SpO₂ (%)  | 98.00 ± 0.919   | 97.82 ± 1.059    | 98.03 ± 1.000    | 98.05 ± 0.909    | 0.504       |
| Baseline SBP (mm Hg) | 128.32 ± 17.057 | 126.75 ± 17.317  | 128.11 ± 17.540  | 124.85 ± 15.294  | 0.624       |
| Baseline DBP (mm Hg) | 78.91 ± 10.728  | 78.57 ± 11.727   | 80.25 ± 9.548    | 75.46 ± 10.499   | 0.073       |
| Baseline HR (bpm)  | 85.46 ± 16.260  | 82.86 ± 14.992   | 84.43 ± 12.993   | 84.35 ± 14.303   | 0.793       |

Data are presented as mean ± SD, or number (%).

BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, IHD ischemic heart disease, DBP diastolic blood pressure, SBP systolic blood pressure, HR heart rate
Evaluation of anesthesia-related indices

Induction times of group P, PK1, PK2, and PK3 were 68.52 ± 18.394, 64.83 ± 13.543, 62.23 ± 15.197, and 61.35 ± 14.470 s, respectively (P = 0.041). The induction time of group PK3 was 7.17 s shorter than that of group P. There were 8, 9, 8, and 5 patients who experienced an awakening delay in groups P, PK1, PK2, and PK3, respectively (P = 0.716). There were no significant differences in procedure time, orientation recovery time, and awakening status between the groups (Table 3).

Incidence of adverse events

We did not find any significant clinical complications during the study. However, the recorded adverse

![Fig. 4](image)

**Fig. 4** The results of repeated measurements of hemodynamic parameters. Systolic blood pressure (A), diastolic blood pressure (B), heart rate (C), and pulse oximetry (D) of patients treated with propofol alone or in combination with different doses of esketamine during gastrointestinal endoscopy.

| Table 2 The AUC of SBP, DBP, HR, and SpO2 |
|---------------------------------------------------|
| Group | Group PK1 | Group PK2 | Group PK3 | P value |
|--------|-----------|-----------|-----------|---------|
| AUC (T0–T6) of SBP | 97.10 ± 57.372 | 84.85 ± 46.859 | 93.26 ± 40.072 | 77.83 ± 40.767 | 0.097 |
| AUC (T0–T6) of DBP | 51.12 ± 20.910 | 51.39 ± 26.653 | 47.71 ± 19.993 | 44.49 ± 21.689 | 0.253 |
| AUC (T0–T6) of HR | 52.82 ± 42.436 | 55.76 ± 35.907 | 49.92 ± 28.269 | 52.87 ± 36.547 | 0.838 |
| AUC (T0–T6) of SpO2 | 8.51 ± 4.411 | 8.52 ± 4.842 | 6.81 ± 3.887 | 7.70 ± 4.406 | 0.087 |

Data are presented as mean ± SD.

AUC the area under the curve, DBP diastolic blood pressure, SBP systolic blood pressure, HR heart rate.

| Table 3 Anesthesia-related indices |
|-----------------------------------|
| Group | Group PK1 | Group PK2 | Group PK3 | P value |
| Induction time (s) | 68.52 ± 18.394 | 64.83 ± 13.543 | 62.23 ± 15.197 | 61.35 ± 14.470 | 0.041 |
| Procedure time (min) | 20.54 ± 6.917 | 19.31 ± 4.603 | 21.23 ± 6.675 | 20.51 ± 5.420 | 0.325 |
| Orientation recovery time (min) | 14.26 ± 3.989 | 14.22 ± 4.615 | 14.17 ± 3.547 | 15.02 ± 3.851 | 0.584 |
| Awakening status (D) | 8 (12.3%) | 9 (13.8%) | 8 (12.3%) | 5 (7.7%) | 0.716 |

Data are presented as mean ± SD or n (%); D, delayed; ※P < 0.05 compared with group P.
events included injection pain, hypoxemia, hypotension, cough, body movement, dizziness, excessive oral secretion (two patients in group PK3), hypertension (one patient in group PK1), and psychotomimetic effects (Tables 4 and 5). Compared with group P, group PK3 showed less cough ($P = 0.048$) and body movement ($P = 0.001$). One patient in group PK1 developed an unintentional tremor, which gradually disappeared after half an hour of rest. One patient in group P and one in group PK3 had unintentional lacrimation without depression or sadness. One patient in group PK3 was agitated, reporting a very pleasant mood and involuntarily wanting to laugh. One patient in group PK3 had nightmares and felt tormented. No arrhythmia, nausea and vomiting, apnea (Table 4), hallucinations, delirium, depression, and other psychoactive effects were observed (Table 5).

**MMSE results**

We performed MMSE before sedation and 10 min after the patient’s awakening. There were no significant changes in MMSE scores after sedation ($P = 0.210$) in any of the groups. There were also no significant differences among the four groups ($P = 0.551$, Table 6).

**Discussion**

The increased use of the painless GI endoscopy has led to an increase in sedation practices for patients [6, 9], and this study aimed to evaluate the efficacy and safety of esketamine–propofol combination compared to propofol alone in GI endoscopy. We found that the use of 0.1 mg/kg and 0.2 mg/kg esketamine reduced the need for propofol by 13.92% and 18.76%, respectively. The combination also shortened the induction time and reduced the incidence of cough and body movement during GI endoscopy. The results of this study indicated a similar performance of the combination esketamine–propofol and propofol alone in terms of hemodynamic stability and adverse events.

In this study, subanesthetic doses of esketamine combined with propofol showed a significant reduction in propofol consumption per minute compared with propofol alone during the GI endoscopy. This result showed the efficacy of the subanesthetic dose of esketamine–propofol combination during GI endoscopy sedation. Yang

---

**Table 4** Adverse events

|                      | Group P | Group PK1 | Group PK2 | Group PK3 | $P$ value |
|----------------------|---------|-----------|-----------|-----------|-----------|
| Injection pain       | 3 (4.6%)| 7 (10.8%) | 2 (3.1%)  | 1 (1.5%)  | 0.149     |
| Hypoxemia            | 14 (21.5%)| 16 (24.6%)| 23 (35.4%)| 16 (24.6%)| 0.297     |
| Hypotension          | 11 (16.9%)| 8 (12.3%) | 3 (4.6%)  | 4 (6.2%)  | 0.072     |
| Cough                | 46 (70.8%)| 34 (52.3%)| 37 (56.9%)| 31 (47.7%)| 0.048     |
| Body movement        | 54 (83.1%)| 55 (84.6%)| 42 (64.6%)| 39 (60.0%)| 0.001     |
| Dizziness            | 7 (10.8%) | 9 (13.8%) | 6 (9.2%)  | 11 (16.9%)| 0.563     |
| Excessive oral secretion | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.247     |
| Hypertension         | 0 (0%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 1.000     |
| Arrhythmia           | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |
| Nausea and vomiting  | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |
| Apnea                | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |

Data are presented as number (%); ※$P < 0.05$ compared with group P, †$P < 0.05$ compared with group PK1

**Table 5** Psychoactive effects

|                      | Group P | Group PK1 | Group PK2 | Group PK3 | $P$ value |
|----------------------|---------|-----------|-----------|-----------|-----------|
| Tremor               | 0 (0%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 1.000     |
| Lacrimation          | 1 (1.5%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 1.000     |
| Agitation            | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 1.000     |
| Nightmare            | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 1.000     |
| Hallucination        | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |
| Delirium             | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |
| Tristimania          | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000     |

Data are presented as numbers (%)

**Table 6** MMSE results

|                      | Group P | Group PK1 | Group PK2 | Group PK3 | $P$ value |
|----------------------|---------|-----------|-----------|-----------|-----------|
| MMSE (before)        | 27.22 ± 2.661 | 27.66 ± 2.340 | 27.92 ± 2.189 | 28.32 ± 1.880 | 0.551     |
| MMSE (after)         | 28.06 ± 2.480 | 27.82 ± 2.164 | 28.03 ± 2.143 | 28.20 ± 2.009 | 0.551     |

Data are presented as mean ± SD; MMSE: Mini-Mental State Examination
et al. [15] also reported the effectiveness of esketamine as an adjunct to propofol target-controlled infusion for gastrointestinal endoscopy in elderly patients. Eberl and colleagues found that this combination was also effective in Endoscopic retrograde cholangiopancreatography (ERCP). They used low-dose (0.15 mg/kg) esketamine combined with propofol in patients undergoing ERCP and found that low-dose esketamine significantly reduced propofol consumption [16]. Since esketamine has both sedative and analgesic effects, esketamine combined with propofol deepens the level of sedation, causing a reduction in rescue doses of propofol during GI endoscopy and finally leading to the reduction of propofol consumption.

Importantly, esketamine is a very new medication being used clinically; thus, it is necessary to evaluate its safety profiles during GI endoscopy sedation. We recorded several elements during the procedure, which included hemodynamic characteristics, induction time of anesthesia, awakening and recovery status, cough, body movement, adverse events, and cognitive function.

We did not find any significant difference among the four groups in terms of hemodynamic characteristics, including HR, SBP, and DBP, at different time points. However, SBP, DBP, and HR decreased immediately after administration of induction and increased to the baseline value at the time before patients left the operating room in all four groups. In contrast, another study showed that the combination of esketamine and propofol caused more stable hemodynamics [15]. The doses of esketamine in that study were 0.25 mg/kg and 0.5 mg/kg, which are relatively higher than the concentrations in our study. With sympathetic excitatory effects of esketamine, the hemodynamics of group PK would theoretically be more stable than that of group P [17]. However, the dose of esketamine used in our study was low and the sympathetic excitatory effect of esketamine may be offset by the cardiovascular depression of relatively high doses of propofol during the procedure.

Induction with 0.2 mg/kg esketamine combined with propofol shortened the induction time of anesthesia in our study. However, another study showed no difference in the induction time between ketamine combined with propofol and propofol alone when applied to painless GI endoscopy in elderly people [11]. The higher potency of esketamine compared with ketamine may be a possible reason for the shorter induction time. As for awakening and recovery status, our study and other studies [11, 16] found no differences between esketamine–propofol combination and propofol alone, suggesting that esketamine may not affect the awakening of patients sedated with propofol. Additionally, in a study of esketamine compared with ketamine applied to gastroscopy, it was found that the recovery time and orientation recovery time were shorter in patients with esketamine, suggesting that esketamine is more suitable for gastroscopy than ketamine [12]. Avoiding cough and body movement is of great importance for improving the comfort of patients and quality of endoscopy. In this study, we found that the group treated with 0.2 mg/kg esketamine combined with propofol had a lower incidence of cough and body movement. Yin et al. [11] also found that the incidence of cough and body movement was lower when elderly patients were sedated with ketamine combined with propofol during GI endoscopy.

We also evaluated several types of adverse events to estimate the safety of esketamine sedation, including hypotension, hypoxemia, propofol injection pain, dizziness, excessive oral secretion, hypertension, arrhythmia, nausea and vomiting, and psychic symptoms. Stable hemodynamic parameters without significant respiration depression or other adverse events were found with the combination of propofol and esketamine. Eberl et al. [16] also found no differences in the incidence of adverse events with low-dose esketamine combined with propofol compared with alfentanil combined with propofol for ERCP. Yang’s study did not find significant clinical complications and psychotomimetic effects of the coadministration of a relatively high dose of esketamine and propofol for the procedure of gastrointestinal endoscopy [15].

In our study, psychic symptoms such as involuntary tremors, involuntary lacrimation, agitation, and nightmares were observed, but no hallucinations, delirium, or depression were found. Previous studies have also shown that the combination of ketamine and propofol is beneficial for reducing the incidence of psychotomimetic effects [11, 18, 19]. However, the mechanisms underlying this disorder remain unknown. MMSE is a relatively simple scale of cognitive function and it is widely used in the diagnosis of psychopathology-related disorders [20]. In one study, MMSE scores measured 15 min after low-dose ketamine combined with propofol was applied to patients undergoing ambulatory surgery were higher than those in the propofol alone group in three domains of cognitive function in MMSE (orientation, attention, and recall) [21]. However, we did not find any differences in MMSE scores among the four groups in our study. To conclude, esketamine is effective for GI endoscopy sedation with proper safety.

There are still some limitations to our study. First, since ketamine was not available in most hospitals in China, we could not set up a group of ketamine patients for comparison with esketamine. Second, this study did not apply the depth of anesthesia to assess the depth of sedation, but we judged the depth of sedation through the disappearance of eyelash reflex and the absence of cough and body movement. Third, the doses of esketamine set in this study were all subanesthetic doses, and the doses used were relatively low. Additional studies with 0.3 mg/kg, 0.4 mg/kg, and 0.5 mg/kg esketamine can be considered. Fourth, since we assessed the awakening
status of patients at 2-min intervals, the recording of awakening time may be delayed, so we adopted the method of awakening status assessment (more than 6 min was defined as delayed awakening). Finally, multicenter studies with larger sample sizes are needed to confirm our findings.

Conclusions
In this study, we observed that in painless gastrointestinal endoscopy, propofol combined with 0.2 mg/kg esketamine had a shorter induction time, lower incidence of cough and body movement, and less propofol consumption per minute than propofol alone; there was no effect on recovery time, hemodynamic stability, postoperative cognitive function, and the incidence of adverse events and psychotomimetic effects.

Acknowledgements
We thank the staffs of the Department of Anesthesiology and Endoscopy Center of the first affiliated hospital of Jinan University for their support in conducting this work.

Author contributions
YL and ZL conceived and designed this research. YZ and SL conducted experiments and drafted the manuscript. ZY and QL conducted experiments. SL prepared drugs. JL helped with statistical analysis. All authors read and approved the final manuscript.

Funding
This study was funded by the Clinical Research Fund for Precision and Comfortable Medicine Project of Guangdong Hospital Association of China.

Availability of data and materials
The raw data are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
China Ethics Committee of Registering Clinical Trials approved the study (Ethics Number: CHIECRCT20210050). All methods and procedures involving participants were in accordance with the ethical standards of the Declaration of Helsinki and China Ethics Committee of Registering Clinical Trials. All participants signed the informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declared no conflict of interest in the content of this article.

Author details
1. Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China. 2. Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Received: 27 March 2022 Accepted: 3 August 2022 Published online: 20 August 2022

References
1. Wallace MB, Wang KK, Adler DG, Rastogi A. Recent advances in endoscopy. Gastroenterology. 2017;153(2):364–81.
2. Skovlund E, Brethauer M, Grotmol T, Larsen IK, Hoff G. Sensitivity of pain rating scales in an endoscopy trial. Clin J Pain. 2005;21(4):292–6.
3. Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorowski JD Jr. AGA Institute review of endoscopic sedation. Gastroenterology. 2007;133(2):675–701.
4. Early DS, Lightdale JR, Vargo JJ 2nd, Acosta RD, Chandrasekhar V, Chatrathi KY, Evans JA, Fisher DA, Fonkaloul L, Hwang JH, et al. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2018;87(2):327–37.
5. Maghboool M, Khosravi T, Vojdani S, Chajian MR, Esmaeili F, Amani A, Rezayat F, Nasimi Doost Azgomi R, Mehraban SS, Hashempur MH. The effects of eugenol nanoemulsion on pain caused by arteriovenous fistula cannulation in hemodialysis patients: a randomized double-blinded controlled cross-over trial. Complement Ther Med. 2020;52:102440.
6. Cohen LB, Wessler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, Aisenberg J. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol. 2006;101(5):967–74.
7. Hegde SR, Iffrig K, Li T, Downey S, Heller SJ, Tokar J, Haluszka O. Double-balloon enteroscopy in the elderly: safety, findings, and diagnostic and therapeutic success. Gastrointest Endosc. 2010;71(6):983–9.
8. Nishizawa T, Suzuki H. Propofol for gastrointestinal endoscopy. United Eur Gastroenterol. 2018;6(6):801–5.
9. Rex DK. Review article: moderate sedation for endoscopy: sedation regimens for non-anaesthesiologists. Aliment Pharmacol Ther. 2006;24(2):163–71.
10. Wadhwa V, Issa O, Gang S, Lopez R, Sanaka MR, Vargo JJ. Similar risk of cardiopulmonary adverse events between propofol and traditional anesthesia for gastrointestinal endoscopy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(2):194–206.
11. Yin S, Hong J, Sha T, Chen Z, Guo Y, Li C, Liu Y. Efficacy and tolerability of sufentanil, dexmedetomidine, or ketamine added to propofol-based sedation for gastrointestinal endoscopy in elderly patients: a prospective, randomized, Controll Trial Clin Ther. 2019;41(9):1864–1877.e1860.
12. Wang J, Huang J, Yang S, Cui C, Ye L, Wang SY, Yang GP, Pei Q. Pharmacokinetics and safety of esketamine in Chinese patients undergoing painless gastroscopy in comparison with ketamine: a randomized, open-label clinical study. Drug Des Devel Ther. 2019;13:4135–44.
13. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–60.
14. Galea M, Woodward M. Mini-mental state examination (MMSE). Aust J Physiother. 2005;51(3):198.
15. Yang H, Zhao Q, Chen HY, Liu W, Ding T, Yang B, Song JC. The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: a randomized controlled trial. Br J Clin Pharmacol. 2022;88(3):1279–87.
16. Eberl S, Koers L, van Hooft J, de Jong E, Hermanides J, Hollmann MW, Preckel B. The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: a randomised controlled multicentre trial. Eur J Anaesthesiol. 2020;37(5):394–401.
17. Chandar R, Jagadisani B, Vasudevan A. Propofol-ketamine and propofol-fentanyl combinations for nonanesthetist-administered sedation. J Pediatr Gastroenterol Nutr. 2015;60(6):762–8.
18. Zou L, Tian SY, Quan X, Ye TH. Psychedic effects of subanesthetic doses of ketamine. Zhonggguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae. 2009;31(1):68–72.
19. Nagata A, Nakao S, Miyamoto E, Inada T, Tooyama I, Kimura H, Shingu K. Propofol inhibits ketamine-induced c-fos expression in the rat posterior cingulate cortex. Anesth Analg. 1998;87(6):1416–20.
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
21. Mortero RF, Clark LD, Tolan MM, Metz RJ, Tsuenda K, Sheppard RA. The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain. Anesth Analg. 2001;92(6):1465–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.